시장보고서
상품코드
1120708

세계의 유도만능줄기세포(iPSC) 시장(2022년판)

Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022

발행일: | 리서치사: BioInformant Worldwide LLC | 페이지 정보: 영문 326 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 유도만능줄기세포(iPSC) 시장에 대해 조사했으며, iPSC 업계의 현황과 역사, 임상시험 상황 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트의 개요

제2장 서론

제3장 유도만능줄기세포(iPSC) 업계의 현황

  • iPSC를 이용한 자가 세포치료의 진보
  • 자가 iPSC 유래 세포 제품의 제조 타임라인
  • iPSC 생산의 비용
  • iPSC 생산의 자동화
  • 동종 iPSC의 기세
  • 줄기세포 업계 전체에서 iPSC 기반 연구의 점유율
  • iPSC 기업의 주요 주력 분야
  • 시판 iPSC 유래 세포 유형
  • 독성 시험 어세이에서 iPSC 유래 세포 유형의 상대적인 사용
  • 현재 이용 가능한 iPSC 기술

제4장 유도만능줄기세포(iPSC)의 역사

제5장 유도만능줄기세포(iPSC)에 관한 연구 발표

제6장 유도만능줄기세포(iPSC) : 특허 상황 분석

제7장 상황 : 임상시험 상황

  • 문헌 및 데이터베이스 검색
  • 매년 iPSC 임상시험 수
  • iPSC 연구 디자인
  • 상용화 가능성이 있는 iPSC 기반 임상시험

제8장 유도만능줄기세포(iPSC)의 연구 자금

제9장 유도만능줄기세포(iPSC) 부문의 M&A, 협업 및 자금조달 활동

  • iPSC 분야의 합병·인수(M&A)
  • iPSC 분야의 제휴·협업·라이선싱 계약
  • 벤처캐피털 자금조달과 IPO

제10장 유도만능줄기세포(iPSC)의 생성 : 개요

  • 리프로그래밍 요인
  • iPSC 전달 방법의 통합
  • 비통합 전달 시스템
  • iPSC를 생성하기 위한 전달 방법의 비교
  • iPS 세포 제작에서의 유전자 편집 기술

제11장 인간 iPSC 뱅킹

제12장 유도만능줄기세포(iPSC)의 생물의학적 응용

  • 기초 연구에서의 iPS
  • Drug Discovery에서의 iPSC
  • 독물 학연구에서의 iPSC
  • 질환 모델링에서의 iPSC
  • 세포 기반 치료에서의 iPSC
  • 기타 응용
  • 동물 보호에서의 iPSC

제13장 시장 개요

  • 세계의 iPSC 시장, 지역별
  • 세계의 iPSC 시장, 기술별
  • 세계의 iPSC 시장, 생물의학적 응용별
  • 세계의 iPSC 시장, 파생 세포 유형별
  • 시장 촉진요인
  • 시장 억제요인

제14장 기업 개요

  • Accellta
  • AddGene, Inc.
  • Allele Biotechnology, Inc
  • ALSTEM, Inc
  • Altos Labs
  • AMS Biotechnology Ltd.
  • Aspen Neuroscience, Inc
  • Astellas Pharma, Inc.
  • Avery Therapeutics
  • Axol Bioscience Ltd.
  • Bit.bio
  • BlueRock Therapeutics
  • BrainXell
  • Brooklyn Immuno Therapeutics
  • Catalent Biologics
  • Celogics, Inc.
  • Cellaria
  • CellGenix, GmbH
  • Cellino Biotech
  • Cellular Engineering Technologies(CET)
  • Censo Biotechnologies, Ltd
  • Century Therapeutics, Inc
  • Citius Pharmaceuticals, Inc
  • Clade Therapeutics
  • Creative Bioarray
  • Curi Bio
  • Cynata Therapeutics Ltd.
  • Cytovia Therapeutics
  • DefiniGEN
  • Editas Medicine
  • ElevateBio
  • Elixirgen Scientific, Inc.
  • Evia Bio
  • Evotec A.G
  • Exacis Biotherapeutics
  • Eyestem
  • Fate Therapeutics
  • FUJIFILM Cellular Dynamics, Inc.(FCDI)
  • Heartseed, Inc
  • HebeCell
  • Helios K.K.
  • Hera BioLabs
  • Hopstem Biotechnology
  • Implant Therapeutics, Inc
  • iPS Portal, Inc
  • I Peace, Inc.
  • iXCells Biotechnologies
  • Kytopen
  • LizarBio Therapeutics
  • Lonza Group, Ltd
  • Matricelf
  • Merck/Sigma Aldrich
  • Megakaryon Corporation
  • Metrion Biosciences, Ltd
  • Mogrify
  • Ncardia
  • NeuCyte
  • Neukio Biotherapeutics
  • Newcells Biotech, Ltd
  • NEXEL Co., Ltd.
  • Orizuru Therapeutics, Inc.
  • Phenocell SAS
  • Platelet BioGenesis
  • Pluristyx
  • ReNeuron
  • REPROCELL USA, Inc.
  • RxCell, Inc.
  • SCG Cell Therapy Pte Ltd
  • Shoreline Biosciences
  • Stemson Therapeutics
  • Stemina Biomarker Discovery
  • Synthego Corp.
  • Tempo Bioscience
  • Thyas, Co., Ltd.
  • Universal Cells
  • ViaCyte, Inc
  • Vita Therapeutics
  • XCell Science, Inc.
  • Yashraj Biotechnology, Ltd
  • YiPCELL
KSA 22.09.08

Executive Summary

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:

  • Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models "in a dish".
  • Drug Development and Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
  • Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine.
  • Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.
  • Research Tools: iPSCs and iPSC-derived cell types are being widely used within basic and applied research applications.
  • Other Applications: Other applications of iPSCs include their integration into 3D bioprinting, tissue engineering, and clean meat production.

Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and clinical trials worldwide. There are also over 100 clinical trials underway that do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest.

2013 was a landmark year because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Dr. Masayo Takahashi, it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world first, Cynata Therapeutics received approval in 2016 to launch the first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. CYP-001 is a iPSC-derived MSC product. In this historic trial, CYP-001 met its clinical endpoints and produced positive safety and efficacy data for the treatment of steroid-resistant acute GvHD.

Given this early success, Cynata is has advanced its iPSC-derived MSCs into Phase 2 trials for the severe complications associated with COVID-19, as well as GvHD and critical limb ischemia (CLI). It is also undertaking an impressive Phase 3 trial that will utilize Cynata's iPSC-derived MSC product, CYP-004, in 440 patients with osteoarthritis (OA). This trial represents the world's first Phase 3 clinical trial involving an iPSC-derived cell therapeutic product and the largest one ever completed. Not surprisingly, the Japanese behemoth FUJIFILM has been involved with the co-development and commercialization of Cynata's iPSC-derived MSCs through its 9% ownership stake in the company.

Many market competitors are also commercializing iPSC-derived products for use in drug development and discovery, disease modeling, and toxicology testing. Across the broader iPSC sector, FUJIFILM CDI (FCDI) is one of the largest and most dominant players. Cellular Dynamics International (CDI) was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time. The feat was accomplished simultaneously by Dr. Shinya Yamanaka's lab in Japan. FUJIFILM acquired CDI in April 2015 for $307 million. Today, the combined company is the world's largest manufacturer of human cells created from iPSCs for use in research, drug discovery and regenerative medicine applications.

Another iPSC specialist is ReproCELL, a company that was established as a venture company originating from the University of Tokyo and Kyoto University in 2009. It became the first company worldwide to make iPSC products commercially available when it launched its ReproCardio product, which are human iPSC-derived cardiomyocytes. Within the European market, the dominant competitors are Evotec, Ncardia, and Axol Bioscience. Headquartered in Hamburg, Germany, Evotec is a drug discovery alliance and development partnership company. It is developing an iPSC platform with the goal to industrialize iPSC-based drug screening as it relates to throughput, reproducibility, and robustness. Today, Evotec's infrastructure represents one of the largest and most advanced iPSC platforms globally.

Ncardia was formed through the merger of Axiogenesis and Pluriomics in 2017. Its predecessor, Axiogenesis, was founded in 2011 with an initial focus on mouse embryonic stem cell-derived cells and assays. When Yamanaka's iPSC technology became available, Axiogenesis became the first European company to license it in 2010. Today, the combined company (Ncardia) is a global authority in cardiac and neural applications of human iPSCs. Founded in 2012, Axol Bioscience is a smaller but noteworthy competitor that specializes in iPSC-derived products. Headquartered in Cambridge, UK, it specializes in human cell culture, providing iPSC-derived cells and iPSC-specific cell culture products.

Of course, the world's largest research supply companies are also commercializing a diverse range of iPSC-derived products and services. Examples of these companies include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and countless others. In total, at least 80 market competitors now offer a diverse range of iPSC products, services, technologies, and therapeutics.

This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development. It covers the current status of iPSC research, biomedical applications, manufacturing technologies, patents, and funding events, as well as all known trials for the development of iPSC-derived cell therapeutics worldwide. Importantly, it profiles leading market competitors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2029.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary

2. INTRODUCTION

3. CURRENT STATUS OF iPSC INDUSTRY

  • 3.1. Progress Made in Autologous Cell Therapy using iPSCs
    • 3.1.1. Examples of Autologous iPSC-derived Cell Therapies in Development
  • 3.2. Manufacturing Timeline for Autologous iPSC-Derived Cell Products
  • 3.3. Cost of iPSC Production
  • 3.4. Automation in iPSC Production
  • 3.5. Allogeneic iPSCs Gaining Momentum
    • 3.5.1. Ongoing Clinical Trials involving Allogeneic iPSCs
  • 3.6. Share of iPSC-based Research within the Overall Stem Cell Industry
  • 3.7. Major Focus Areas of iPSC Companies
  • 3.8. Commercially Available iPSC-derived Cell Types
  • 3.9. Relative use of iPSC-derived Cell Types in Toxicology Testing Assays
  • 3.10. Currently Available iPSC Technologies
    • 3.10.1. Brief Descriptions of some Recently introduced iPSC-related Technologies
      • 3.10.1.1. Nucleofector Technology
      • 3.10.1.2. opti-ox Technology
      • 3.10.1.3. MOGRIFY Technology
      • 3.10.1.4. Transcription Factor-Based iPSC Differentiation Technology
      • 3.10.1.5. Flowfect Technology
      • 3.10.1.6. Technology for Mass Production of Platelets from Megakaryocytes
      • 3.10.1.7. SynFire Technology

4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (iPSCS)

  • 4.1. First iPSC Generation from Mouse Fibroblasts, 2006
  • 4.2. First Human iPSC Generation, 2007
  • 4.3. Creation of CiRA, 2010
  • 4.4. First High-Throughput Screenining using iPSCs, 2012
  • 4.5. First iPSC Clinical Trial Approved in Japan, 2013
  • 4.6. First iPSC-RPE Cell Sheet Transplantation for AMD, 2014
  • 4.7. EBiSC Founded, 2014
  • 4.8. First Clinical Trial using Allogeneic iPSCs for AMD, 2017
  • 4.9. Clinical Trial for Parkinson's disease using Allogeneic iPSCs, 2018
  • 4.10. Commercial iPSC Plant SMaRT Established, 2018
  • 4.11. First iPSC Therapy Center in Japan, 2019
  • 4.12. First U.S. Based NIH-Sponsored Clinical Trial using iPSCs, 2019
  • 4.13. Cynata Therapeutics' World's Largest Phase III Clinical Trial, 2020
  • 4.14. Tools and Know-how to Manufacture iPSCs in Clinical Trials, 2021
  • 4.15. Production of In-House iPSCs using Peripheral Blood Cells, 2022

5. RESEARCH PUBLICATIONS ON iPSCS

  • 5.1. The Fast Growth in iPSC Publications
    • 5.1.1. PubMed Publications on Pathophysiological Research
    • 5.1.2. PubMed Papers in Reprogramming
    • 5.1.3. PubMed Papers in iPSC Differentiation
    • 5.1.4. PubMed Papers on the use of iPSCs in Drug Discovery
    • 5.1.5. PubMed Papers on iPSC-based Cell Therapy
  • 5.2. Percent Share of Published Articles by Disease Type
  • 5.3. Percent Share of Articles by Country

6. iPSC: PATENT LANDSCAPE ANALYSIS

  • 6.1. Legal Status of iPSC Patents
  • 6.2. Patents by Assignee Organization Type
  • 6.3. Ownership of Patent Families by Assignee Type
  • 6.4. Top Inventors of iPSC Patents
  • 6.5. Top Ten iPSC Inventors
  • 6.6. Most Cited Five iPSC Patents
  • 6.7. Leading Patent Filing Jurisdictions
  • 6.8. Number of Patent Families by Year of Filing
  • 6.9. Patents Representing Different Disorders
  • 6.10. iPSC Patents on Preparation Technologies
  • 6.11. Patents on Cell Types Differentiated from iPSCs
  • 6.12. Patent Application Trends Disease-Specific Technologies

7. iPSC: CLINICAL TRIAL LANDSCAPE

  • 7.1. Literature and Database Search
  • 7.2. Number of iPSC Clinical Trials by Year
  • 7.3. iPSC Study Designs
    • 7.3.1. Therapeutic and Non-Therapeutic Studies
    • 7.3.2. Non-Therapeutic Clinical Trials by Use
      • 7.3.2.1. Top Ten Countries with the Ongoing Non-Therapeutic Studies
      • 7.3.2.2. Diseases Targeted by Non-Therapeutic Studies
    • 7.3.3. Therapeutic Studies
      • 7.3.3.1. Therapeutic Studies by Phase of Study
      • 7.3.3.2. Therapeutic Studies by Disease Type
      • 7.3.3.3. Examples of Therapeutic Interventional Studies
      • 7.3.3.4. Future Outlook for Therapeutic Clinical Trials using iPSCs
  • 7.4. iPSC-Based Clinical Trials with Commercialization Potential

8. RESEARCH FUNDING FOR iPSCS

  • 8.1. Value of NIH Funding for iPSC Research
  • 8.2. Partial List of NIH Funded iPSC Research Projects in 2022

9. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN iPSC SECTOR

  • 9.1. Mergers and Acquisitions (M&A) in iPSC Sector
    • 9.1.1. Evotec & Rigenerand
    • 9.1.2. Catalent & RheinCell Therapeutics
    • 9.1.3. Axol Bioscience & Censo Biotechnologies
    • 9.1.4. Bayer AG & BlueRock
    • 9.1.5. Pluriomics & Axiogenesis
  • 9.2. Partnership/Collaboration/Licensing Deals in iPSC Sector
    • 9.2.1. Evotec & Sernova
    • 9.2.2. Evotec SE & Almirall, SA
    • 9.2.3. Quell Therapeutics & Cellistic
      • 9.2.3.1. Terms of the Collaboration
    • 9.2.4. MDimmune & YiPSCELL
    • 9.2.5. EdiGene & Neukio Biotherapeutics
    • 9.2.6. Matricelf & Ramot
    • 9.2.7. Evotec & Boehringer Ingelheim
    • 9.2.8. Plurityx, Pancella & Implant Therapeutics
    • 9.2.9. Century Therapeutics & Bristol Myers Squibb
    • 9.2.10. Terms of the Collaboration
    • 9.2.11. Fujifilm Cellular Dynamics & Pheno Vista Biosciences
    • 9.2.12. Metrion Biosciences & Bioqube Ventures
    • 9.2.13. Cytovia Therapeutics & Cellectis
    • 9.2.14. Exacis Biotherapeutics & CCRM
    • 9.2.15. Cynata Therapeutics & Fujifilm Corporation
    • 9.2.16. Bone Therapeutics & Implant Therapeutics
    • 9.2.17. REPROCELL & TEXCELL
    • 9.2.18. Jacobio & Herbecell
    • 9.2.19. NeuCyte & KIF1A.ORG
    • 9.2.20. Kite & Shoreline Biosciences
    • 9.2.21. Neurophth Therapeutics & Hopstem Biotechnology
    • 9.2.22. Allele Biotech & Cellatoz
    • 9.2.23. BlueRock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics
    • 9.2.24. Newcells & Takeda
    • 9.2.25. Biocentriq & Kytopen
    • 9.2.26. Fujifilm Cellular Dynamics & Sana Biotechnology
    • 9.2.27. Evotec & Medical Center Hamburg-Eppendorf (UKE)
    • 9.2.28. NeuCyte & Seaver Autism Center for Research and Treatment
    • 9.2.29. Cytovia Therapeutics & National Cancer Institute
    • 9.2.30. Mogrify & MRC Laboratory of Molecular Biology
  • 9.3. Venture Capital Funding and IPOs
    • 9.3.1. Aspen Neuroscience
    • 9.3.2. Axol Biosciences Ltd.
    • 9.3.3. Thyas Co. Ltd.
    • 9.3.4. Synthego
    • 9.3.5. Cellino Biotech, Inc.
    • 9.3.6. Curi Bio
    • 9.3.7. Ncardia
    • 9.3.8. Evotec SE
    • 9.3.9. bit.bio
    • 9.3.10. Clade Therapeutics
    • 9.3.11. Shoreline Biosciences
    • 9.3.12. Kytopen
    • 9.3.13. Cytovia Therapeutics & CytoLynx
    • 9.3.14. TreeFrog Therapeutics
    • 9.3.15. HebeCell Corporation
    • 9.3.16. Neukio Biotherapeutics
    • 9.3.17. Stemson Therapeutics
    • 9.3.18. Vita Therapeutics
    • 9.3.19. Century Therapeutics
    • 9.3.20. Heartseed
    • 9.3.21. Mogrify
    • 9.3.22. Metrion Biosciences
    • 9.3.23. Axol Biosciences
    • 9.3.24. Axol Bioscience
    • 9.3.25. Elevate Bio
    • 9.3.26. Vita Therapeutics

10. GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW

  • 10.1. Reprogramming Factors
    • 10.1.1. Pluripotency-Associated Transcription Factors and their Functions
    • 10.1.2. Different Combinations of Factors for Different Cell Sources
    • 10.1.3. Delivery of Reprogramming Factors
  • 10.2. Integrating iPSC Delivery Methods
    • 10.2.1. Retroviral Vectors
    • 10.2.2. Lentiviral Vectors
    • 10.2.3. piggyBac (PB) Transposon
  • 10.3. Non-Integrative Delivery Systems
    • 10.3.1. Adenoviral Vectors
    • 10.3.2. Sendai Viral Vectors
    • 10.3.3. Plasmid Vectors
    • 10.3.4. Minicircles
    • 10.3.5. oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1) based Episomes
    • 10.3.6. RNA
    • 10.3.7. Proteins
  • 10.4. Comparison of Delivery Methods for generating iPSCs
  • 10.5. Genome Editing Technologies in iPSC Generation
    • 10.5.1. CRISPR/Cas9

11. HUMAN iPSC BANKING

  • 11.1. Cell Sources for iPSC Banking
  • 11.2. Reprogramming Methods used in IPSC Banking
  • 11.3. Factors used in Reprogramming in Different Banks
  • 11.4. Workflow in iPSC Banks
  • 11.5. Existing iPSC Banks
    • 11.5.1. California Institute for Regenerative Medicine (CIRM)
      • 11.5.1.1. CIRM iPSC Repository
      • 11.5.1.2. Key Partnerships Supporting CIRM's iPSC Repository
  • 11.6. Regenerative Medicine Program (RMP)
    • 11.6.1. Research Grade iPSC Lines for Orphan & Rare Diseases with RMP
    • 11.6.2. RMP's Stem Cell Translation Laboratory (SCTL)
  • 11.7. Center for iPS Cell Research and Application (CiRA)
  • 11.8. FiT - Facility for iPS Cell Therapy
  • 11.9. European Bank for Induced Pluripotent Stem Cells (EBiSC)
  • 11.10. Korean Society for Cell Biology (KSCB)
  • 11.11. Human Induced Pluripotent Stem Cell Initiative (HipSci)
  • 11.12. RIKEN - BioResource Research Center (BRC)
  • 11.13. Taiwan Human Disease iPSC Consortium
  • 11.14. WiCell

12. BIOMEDICAL APPLICATIONS OF iPSCS

  • 12.1. iPSCs in Basic Research
    • 12.1.1. To Understand Cell Fate Control
    • 12.1.2. To Understand Cell Rejuvenation
    • 12.1.3. To Understand Pluripotency
    • 12.1.4. To Study Tissue & Organ Development
    • 12.1.5. To Produce Human Gametes from iPSCs
    • 12.1.6. Providers of iPSC-Related Services for Researchers
  • 12.2. iPSCs in Drug Discovery
    • 12.2.1. Advantages
    • 12.2.2. Drug Discovery for Cardiovascular Diseases using iPSCs
    • 12.2.3. Drug Discovery for Neurological Diseases using iPSCs
    • 12.2.4. Drug Discovery for Rare Diseases using iPSCs
  • 12.3. iPSCs in Toxicology Studies
    • 12.3.1. Testing Drugs for DILI
    • 12.3.2. Examples of Drugs Tested in iPSC-derived Cells
    • 12.3.3. Relative use of IPSC-derived Cell Types in Toxicity Testing Studies
  • 12.4. iPSCs in Disease Modeling
    • 12.4.1. Cardiovascular Diseases Modeled with iPSC-derived Cells
  • 12.4.1.1 Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
    • 12.4.2. Modeling Liver Diseases using iPSC-derived Hepatocytes
    • 12.4.3. iPSCs in Neurodegenerative Disease Modeling
    • 12.4.4. iPSC-derived Organoids for Modeling and Diseases
    • 12.4.5. Cancer-Derived iPSCs
  • 12.5. iPSCs in Cell-Based Therapies
    • 12.5.1. Companies Focusing only on iPSC-based Cell Therapy
  • 12.6. Other Novel Applications of iPSCs
    • 12.6.1. iPSCs in Tissue Engineering
      • 12.6.1.1. 3D Bioprinting Techniques
      • 12.6.1.2. Biomaterials
      • 12.6.1.3. 3D Bioprinting Strategies
      • 12.6.1.4. Bioprinting iPSC-derived Cells
    • 12.6.2. iPSCs from Farm Animals
      • 12.6.2.1. Porcine iPSCs
      • 12.6.2.2. Bovine iPSCs
      • 12.6.2.3. Ovine and Caprine iPSCs
      • 12.6.2.4. Equine iPSCs
      • 12.6.2.5. Avian iPSCs
  • 12.7. iPSCs in Animal Conservation
    • 12.7.1. iPSC Lines for the Preservation of Endangered Species of Animals
    • 12.7.2. iPSCs in Wildlife Conservation
    • 12.7.3. iPSCs in Cultured Meat

13. MARKET OVERVIEW

  • 13.1. Global Market for iPSCs by Geography
  • 13.2. Global Market for iPSCs by Technology
  • 13.3. Global Market for iPSCs by Biomedical Application
  • 13.4. Global Market for iPSCs by Derived Cell Type
  • 13.5. Market Drivers
    • 13.5.1. Current Drivers Impacting the iPSC marketplace
  • 13.6. Market Restraints
    • 13.6.1. Economic Issues
    • 13.6.2. Genomic Instability
    • 13.6.3. Immunogenicity
    • 13.6.4. Biobanking

14. COMPANY PROFILES

  • 14.1. Accellta
    • 14.1.1. Technology
    • 14.1.2. Maxells
    • 14.1.3. Singles
    • 14.1.4. Diffentiation
    • 14.1.5. Services
  • 14.2. AddGene, Inc.
    • 14.2.1. Viral Plasmids
  • 14.3. Allele Biotechnology, Inc.
    • 14.3.1. iPSC Reprogramming and Differentiation
    • 14.3.2. cGMP Facility
  • 14.4. ALSTEM, Inc.
    • 14.4.1. Services
    • 14.4.2. iPSC-related Products
    • 14.4.3. Human iPS Cell Lines
    • 14.4.4. Inducible iPS Cell Lines
    • 14.4.5. Isogenic iPS Cell Lines
    • 14.4.6. Knockout Cell Lines
  • 14.5. Altos Labs
  • 14.6. AMS Biotechnology Ltd. (AMSBIO)
    • 14.6.1. iPSC-derived Cells and Differentiation Kits
    • 14.6.2. iPSC-derived Excitatory Neurons
    • 14.6.3. iPSC-derived Dopaminergic Neurons
    • 14.6.4. iPSC-derived GABAergic Neurons
    • 14.6.5. iPSC-derived Cholinergic Neurons
    • 14.6.6. iPSC-derived Skeletal Muscle
  • 14.7. Aspen Neuroscience, Inc.
    • 14.7.1. Aspen's Clinical Pipeline
  • 14.8. Astellas Pharma, Inc.
    • 14.8.1. Leading Program
  • 14.9. Avery Therapeutics
    • 14.9.1. MyCrdia
  • 14.10. Axol Bioscience Ltd.
    • 14.10.1. iPSC-derived Cells
    • 14.10.2. Disease Models
    • 14.10.3. Services
    • 14.10.4. Custom Cell Services
    • 14.10.5. Stem Cell Reprogramming
    • 14.10.6. Genome Editing
    • 14.10.7. Stem Cell Differentiation
  • 14.11. Bit.bio
    • 14.11.1. Opti-OX Reprogramming Technology
    • 14.11.2. ioCells
    • 14.11.3. ioWild Type Cells
    • 14.11.4. ioGlutamatergic Neurons
    • 14.11.5. ioSkeletal Myocytes
    • 14.11.6. ioGABAergic Neurons
    • 14.11.7. ioDisease Models
    • 14.11.8. ioGlutamatergic Neurons HTT50CAGWT
  • 14.12. BlueRock Therapeutics
    • 14.12.1. CELL + GENE Platform
  • 14.13. BrainXell
    • 14.13.1. Products
      • 14.13.1.1. Spinal Motor Neurons
      • 14.13.1.2. Midbrain Dopaminergic Neurons
      • 14.13.1.3. Cortical Glutamatergic Neurons
      • 14.13.1.4. Mixed Cortical Neurons
      • 14.13.1.5. Cortical Astrocytes
      • 14.13.1.6. Layer V Glutamatergic Neurons
      • 14.13.1.7. Cortical GABAergic Neurons
      • 14.13.1.8. Microglia
      • 14.13.1.9. Medium Spiny Neurons
      • 14.13.1.10. Spinal Astrocytes
  • 14.14. Brooklyn Immuno Therapeutics
    • 14.14.1. Synthetic mRNA
    • 14.14.2. Non-Viral Nucleic Acid Delivery
    • 14.14.3. Cellular Reprogramming
    • 14.14.4. Gene Editing
  • 14.15. Catalent Biologics
    • 14.15.1. Human iPSCs
  • 14.16. Celogics, Inc.
    • 14.16.1. Celo.Cardiomyocytes
  • 14.17. Cellaria
    • 14.17.1. Lung Cancer Cell Models
    • 14.17.2. Breast Cancer Cell Models
    • 14.17.3. Colon Cancer Cell Lines
    • 14.17.4. Ovarian Cancer Cell Lines
    • 14.17.5. Pancreatic Cancer Cell Lines
    • 14.17.6. Cancer Research Custom Services
    • 14.17.7. Stem Cell Services
  • 14.18. CellGenix, GmbH
    • 14.18.1. Products
  • 14.19. Cellino Biotech
    • 14.19.1. Cellino's Technology Platform
  • 14.20. Cellular Engineering Technologies (CET)
    • 14.20.1. Products
    • 14.20.2. iPS Cell Lines
    • 14.20.3. Drug Discovery Services
    • 14.20.4. iPSC Reprogramming Services
  • 14.21. Censo Biotechnologies, Ltd.
    • 14.21.1. Neuroinflammation
    • 14.21.2. Inflammation
    • 14.21.3. Neurobiology
  • 14.22. Century Therapeutics, Inc.
    • 14.22.1. Cell Therapy Platform
    • 14.22.2. Century's Pipeline
  • 14.23. Citius Pharmaceuticals, Inc.
    • 14.23.1. Stem Cell Platform of iMSCs
  • 14.24. Clade Therapeutics
  • 14.25. Creative Bioarray
    • 14.25.1. iPSC Reprogramming Kits
    • 14.25.2. QualiStem Episomal iPSC Reprogramming Kit
    • 14.25.3. QualiStem RNA iPSC Reprogramming Kit
    • 14.25.4. QualiStem Retrovirus iPSC Reprogramming Kit
    • 14.25.5. QualiStem Lentivirus iPSC Reprogramming Kit
    • 14.25.6. QualiStem iPSC Protein Reprogramming Kit
    • 14.25.7. iPSC Characterization Kits
    • 14.25.8. Alkaline Phosphatase Staining Assay
    • 14.25.9. Pluripotency Markers (Protein)
    • 14.25.10. Pluripotency Markers (mRNA)
    • 14.25.11. iPSC Differentiation Kits
    • 14.25.12. QualiStem iPS Cell Cardiomyocyte Differentiation Kit
    • 14.25.13. QualiStem Human iPS Cell Dopaminergic Neuron Differentiation Kit
    • 14.25.14. QualiStem iPS Cell Neural Progenitor Differentiation Kit
    • 14.25.15. QualiStem iPS Cell Endoderm Differentiation Kit
    • 14.25.16. QualiStem iPS Cell Ectoderm Differentiation Kit
    • 14.25.17. QualiStem iPS Cell Mesoderm Differentiation Kit
    • 14.25.18. QualiStem iPS Cell Hepatocyte Differentiation Kit
    • 14.25.19. iPSC Myogenic Progenitor Differentiation kit
  • 14.26. Curi Bio
    • 14.26.1. Disease Model Development
    • 14.26.2. Assay Development
    • 14.26.3. Discovery
    • 14.26.4. Cell Repositories
  • 14.27. Cynata Therapeutics Ltd.
    • 14.27.1. Cymerus Platform
    • 14.27.2. Clinical Development
      • 14.27.2.1. Graft vs. Host Disease
      • 14.27.2.2. Critical Limb Ischemia
      • 14.27.2.3. Osteoarthritis
      • 14.27.2.4. Acute Respiratory Syndrome
      • 14.27.2.5. Diabetic Wounds
      • 14.27.2.6. Preclinical Development
      • 14.27.2.7. Idiopathic Pulmonary Fibrosis
      • 14.27.2.8. Renal Transplantation
      • 14.27.2.9. Asthma
      • 14.27.2.10. Heart Attack
      • 14.27.2.11. Coronary Artery Disease
  • 14.28. Cytovia Therapeutics
    • 14.28.1. Technology
    • 14.28.2. iNK & CAR-iNK Cells
    • 14.28.3. Flex-NK Cell Engagers
  • 14.29. DefiniGEN
    • 14.29.1. OptiDIFF iPSC Platform
    • 14.29.2. Services
      • 14.29.2.1. Phenotypic Screening Services
      • 14.29.2.2. iPSC Differentiation Services
      • 14.29.2.3. Disease Modeling Services
    • 14.29.3. Products
      • 14.29.3.1. Hepatocyte WT
      • 14.29.3.2. NAFLD iPSC-Derived Hepatocytes
      • 14.29.3.3. GSD1a Disease Modeled Hepatocytes
      • 14.29.3.4. A1ATD Disease Modeled Hepatocytes
      • 14.29.3.5. Hepatocyte Familial Hypercholesterolemia (FH)
      • 14.29.3.6. Custom Model Development
      • 14.29.3.7. NAFLD PNPLA3
      • 14.29.3.8. NAFLD TM6SF2 Disease Modeled Hepatocytes
      • 14.29.3.9. Intestinal Organoids
      • 14.29.3.10. Intestinal Monolayer
      • 14.29.3.11. Pancreatic Beta Cells (WT)
      • 14.29.3.12. MODY3 Diabetes
      • 14.29.3.13. Neonatal Diabetes Pancreatic Cells
  • 14.30. Editas Medicine
    • 14.30.1. iPSC-Derived NK Cells
  • 14.31. ElevateBio
    • 14.31.1. Technologies
  • 14.32. Elixirgen Scientific, Inc.
    • 14.32.1. Technology
    • 14.32.2. Services
    • 14.32.3. iPSC Products
    • 14.32.4. Reagents
  • 14.33. Evia Bio
    • 14.33.1. iPSCs Cryopreservation Solutions
  • 14.34. Evotec A.G.
    • 14.34.1. iPSCs Platform
    • 14.34.2. Drug Discoveries
  • 14.35. Exacis Biotherapeutics
    • 14.35.1. ExaCELLs
  • 14.36. Eyestem
    • 14.36.1. Eyecyte-RPE
  • 14.37. Fate Therapeutics
    • 14.37.1. iPSCs Platform
    • 14.37.2. Pipeline
    • 14.37.3. Collaborations
      • 14.37.3.1. Janssen Biotech
      • 14.37.3.2. ONO Pharmaceutical
  • 14.38. FUJIFILM Cellular Dynamics, Inc. (FCDI)
    • 14.38.1. Products
    • 14.38.2. MyCell Custom Services
    • 14.38.3. Disease Modeling Applications
    • 14.38.4. Drug Discovery Applications
    • 14.38.5. Applications in Toxicity Testing
  • 14.39. Heartseed, Inc.
    • 14.39.1. Technology
  • 14.40. HebeCell
    • 14.40.1. Technology
  • 14.41. Helios K.K.
  • 14.42. Hera BioLabs
    • 14.42.1. Services
    • 14.42.2. Products
    • 14.42.3. piggyBac Transposase/Transposon
  • 14.43. Hopstem Biotechnology
    • 14.43.1. Research & Development
    • 14.43.2. Product Pipeline
  • 14.44. Implant Therapeutics, Inc.
    • 14.44.1. Services
  • 14.45. iPS Portal, Inc
    • 14.45.1. Services
      • 14.45.1.1. Research Support and Contract Testing Services
      • 14.45.1.2. Development Support Services
    • 14.45.2. Business Support
  • 14.46. . I Peace, Inc.
    • 14.46.1. Mass Production of iPSCs
  • 14.47. iXCells Biotechnologies
    • 14.47.1. Products
    • 14.47.2. Services
    • 14.47.3. iPS Cell Generation
    • 14.47.4. Genome Editing
    • 14.47.5. iPSC Differentiation
  • 14.48. Kytopen
    • 14.48.1. Flowfect Technology
  • 14.49. LizarBio Therapeutics
    • 14.49.1. Pipeline
  • 14.50. Lonza Group, Ltd.
    • 14.50.1. iPSC Manufacturing Expertise
    • 14.50.2. Nucleofector Technology
  • 14.51. Matricelf
  • 14.52. Merck/Sigma Aldrich
    • 14.52.2. Merck's iPSC Products and Services
  • 14.53. Megakaryon Corporation
    • 14.53.1. Technology
    • 14.53.2. Research and Development Pipeline
    • 14.53.3. Cryopreservable Megakaryon Strain
    • 14.53.4. Treatable Diseases by Products from Megakaryon
  • 14.54. Metrion Biosciences, Ltd.
    • 14.54.1. Cardiac Safety Screening Services
    • 14.54.2. Neuroscience Assay Services
    • 14.54.3. Cardiac Assay Services
    • 14.54.4. Neuroscience Translational Assay Services
    • 14.54.5. Integrated Drug Discovery Service
  • 14.55. Mogrify
    • 14.55.1. Mogrify Platform
    • 14.55.2. epiMogrify Platform
  • 14.56. Ncardia
    • 14.56.1. iPSC Platform
    • 14.56.2. Human iPSC-derived Cell Models
    • 14.56.3. Drug Discovery Solutions
    • 14.56.4. Developing iPSC-derived Cell Types
    • 14.56.5. Assay Development
    • 14.56.6. High-Throughput Screening
  • 14.57. NeuCyte
    • 14.57.1. SynFire Technology
  • 14.58. Neukio Biotherapeutics
    • 14.58.1. iPSC-CAR-NK
  • 14.59. Newcells Biotech, Ltd
    • 14.59.1. Retinal Platform
    • 14.59.2. Kidney Platform
    • 14.59.3. Lung Model
  • 14.60. NEXEL Co., Ltd.
    • 14.60.1. Cardiosight-S
    • 14.60.2. Hepatocyte-S
    • 14.60.3. Neurosight-S
    • 14.60.4. NeXST Cardiac Safety Service
  • 14.61. Orizuru Therapeutics, Inc.
    • 14.61.1. iCM Project
    • 14.61.2. iPIC Project
  • 14.62. Phenocell SAS
    • 14.62.1. Cells and Kits
    • 14.62.2. R&D Outsourcing Services
  • 14.63. Platelet BioGenesis
    • 14.63.1. Technology
  • 14.64. Pluristyx
    • 14.64.1. RTD and RTU Technologies
    • 14.64.2. Products
    • 14.64.3. Services
  • 14.65. ReNeuron
    • 14.65.1. Technology Platform
  • 14.66. REPROCELL USA, Inc.
    • 14.66.1. RNA Reprogramming Kit
    • 14.66.2. NutriStem Culture Medium for Human iPSCs and ES Cells
    • 14.66.3. Induced Pluripotent Stem Cells
    • 14.66.4. StemRNA Neuro
    • 14.66.5. iPSCs Master Cell Bank
  • 14.67. RxCell, Inc.
    • 14.67.1. Services
  • 14.68. SCG Cell Therapy Pte Ltd.
    • 14.68.1. Acquisition of Technology
  • 14.69. Shoreline Biosciences
    • 14.69.1. iNK Cell Platform
    • 14.69.2. iPSC-Derived iMACs
  • 14.70. Stemson Therapeutics
    • 14.70.1. Hair Follicle Biology
  • 14.71. Stemina Biomarker Discovery
    • 14.71.1. Cardio quickPredict
    • 14.71.2. devTOX quickPredict
  • 14.72. Synthego Corp.
    • 14.72.1. Knockout iPSCs
    • 14.72.2. Knock-in iPSCs
  • 14.73. Tempo Bioscience
    • 14.73.1. Human iPSC-derived Sensory Neurons
    • 14.73.2. Human iPS-derived Schwann Cells
    • 14.73.3. Human iPS-derived Phagocytes
    • 14.73.4. Human iPSC-derived CD14+ Monocytes
    • 14.73.5. Human iPSC-derived Cardiomyocytes
    • 14.73.6. hiPSC-derived Kidney Proximal Tubules and Podocyte 3D Spheroids
    • 14.73.7. Human iPSC-derived Osteoblasts
    • 14.73.8. Human iPSC-derived MSCs
    • 14.73.9. Human iPSC-derived Retinal Pigment Epithelials
    • 14.73.10. Human iPS-derived Motor Neurons
    • 14.73.11. Human iPSC-derived Microglia
    • 14.73.12. Human iPSC-derived Keratinocytes
    • 14.73.13. Human iPSC-derived Melanocytes
    • 14.73.14. Human iPSC-derived Dopaminergic Neurons
    • 14.73.15. Human iPSC-derived Cortical Neurons
    • 14.73.16. Human iPSC-derived Oligodendrocyte Progenitor Cells (OPCs)
    • 14.73.17. Human iPSC-derived Astrocytes
    • 14.73.18. Human iPSC-derived Neural Progenitor Cells
  • 14.74. Thyas, Co., Ltd.
    • 14.74.1. iTCR-T (iPSC-derived TCR-T)
    • 14.74.2. iCAR-NK/ILC (iPSC-derived CAR-NK/ILC)
    • 14.74.3. Thya's Product Pipeline
  • 14.75. Universal Cells
    • 14.75.1. Technology
    • 14.75.2. Editing the Genome without Breaking It
    • 14.75.3. Cells for Every Organ
  • 14.76. ViaCyte, Inc.
    • 14.76.1. PEC-01 Cells
    • 14.76.2. Device Engineering
  • 14.77. Vita Therapeutics
    • 14.77.1. Technology
    • 14.77.2. VTA-100
  • 14.78. XCell Science, Inc.
    • 14.78.1. Cell Products
    • 14.78.2. Control Lines
    • 14.78.3. Services
  • 14.79. Yashraj Biotechnology, Ltd.
    • 14.79.1. iPSC and Differentiated Derivatives
      • 14.79.1.1. iPSC-derived Human Cardiomyocytes
      • 14.79.1.2. iPSC-derived Hepatocytes
      • 14.79.1.3. iPSC-derived Astrocytes
      • 14.79.1.4. iPSC-derived Forebrain Motor Neurons
      • 14.79.1.5. iPSC-derived Endothelial Cells
      • 14.79.1.6. iPSC-derived Midbrain Dopaminergic Neurons
  • 14.80. YiPCELL
    • 14.80.1. R&D Programs
    • 14.80.2. MIUChon
    • 14.80.3. MIUKin
    • 14.80.4. MIURon

INDEX OF TABLES

  • TABLE 3.1: Progression of Autologous iPS-derived Cell Therapies toward the Clinic
  • TABLE 3.2: Examples of Autologous iPSC-derived Cell Therapies in Development
  • TABLE 3.3: Examples of Clinical Trials involving Allogeneic iPSCs
  • TABLE 3.4: Currently Available iPSC Technologies
  • TABLE 4.1: Timeline of Important Milestones Reached in iPSC Industry, 2006-2022
  • TABLE 5.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-May 2022
  • TABLE 6.1: Top 20 Inventors of iPSC Patents by Legal Status
  • TABLE 6.2: Top Ten iPSC Inventors
  • TABLE 6.3: Most Cited Five iPSC Patents
  • TABLE 7.1: Recruitment Status of iPSC Clinical Trials
  • TABLE 7.2: Examples of Therapeutic Interventional Studies
  • TABLE 7.2: (CONTINUED)
  • TABLE 7.2: (CONTINUED)
  • TABLE 8.1: A Partial List of Research Projects Supported by NIH, 2022
  • TABLE 9.1: Mergers and Acquisitions (M&A) in iPSC Sector
  • TABLE 9.2: Partnership/Collaboration Deals in iPSC Sector
  • TABLE 9.2: (CONTINUED)
  • TABLE 9.3: Venture Capital Funding and IPOs
  • TABLE 10.1: Pluripotency-Associated Transcription Factors and their Functions
  • TABLE 10.2: Different Combinations of Factors for Different Cell Sources
  • TABLE 10.3: Comparison of Delivery Methods for in Producing iPSCs
  • TABLE 10.4: iPSC Disease Models Generated by CRISPR/Cas9
  • TABLE 10.4: (CONTINUED)
  • TABLE 11.1: Cell Sources and Reprogramming Agents used in iPSC Banks
  • TABLE 11.2: Diseased iPSC Lines Available in CIRM Repository
  • TABLE 11.3: CIRM's iPSC Initiative Awards
  • TABLE 11.4: Research Grade iPSCs Available with RMP
  • TABLE 11.5: Research Grade iPSC Lines for Orphan & Rare Diseases with RMP
  • TABLE 11.6: SCTL's Collaborations
  • TABLE 11.7: A Partial List of iPSC Lines Available with EBiSC
  • TABLE 11.8: List of Disease-Specific iPSCs Available with RIKEN
  • TABLE 11.8: (CONTINUED)
  • TABLE 11.8: (CONTINUED)
  • TABLE 11.10: An Overview of iPSC Banks Worldwide
  • TABLE 12.1: Providers of iPSC Lines & Parts Thereof for Research
  • TABLE 12.2: Drug Discovery for Cardiovascular Diseases using iPSCs
  • TABLE 12.2: (CONTINUED)
  • TABLE 12.2: (CONTINUED)
  • TABLE 12.3: Drug Discovery for Neurological and Neuropsychiatic Diseases using iPSCs
  • TABLE 12.3: (CONTINUED)
  • TABLE 12.4: Drug Discovery for Rare Diseases using iPSCs
  • TABLE 12.5: Examples of Drugs Tested in iPSC-derived Cells
  • TABLE 12.5: (CONTINUED)
  • TABLE 12.6: Published Human iPSC Models
  • TABLE 12.6: (CONTINUED)
  • TABLE 12.6: (CONTINUED)
  • TABLE 12.6: (CONTINUED)
  • TABLE 12.6: (CONTINUED)
  • TABLE 12.7: Partial List of Cardiovascular & other Related Diseases Modeled using iPSCs
  • TABLE 12.8: Liver Diseases and Therapeutic Interventions Modeled using iPSCs
  • TABLE 12.8: (CONTINUED)
  • TABLE 12.9: Examples of iPSC-based Neurodegenerative Disease Modeling
  • TABLE 12.9: (CONTINUED)
  • TABLE 12.9: (CONTINUED)
  • TABLE12.9: (CONTINUED)
  • TABLE 12.10: Organoid Types and Disease Modeling Applications
  • TABLE 12.11: Examples of Cancer-derived iPSCs
  • TABLE 12.12: Diseases Addressed by iPSC-derived Cells in Studies in Advanced Stages
  • TABLE 12.13: Companies focusing exclusively on developing iPSC-based Therapies
  • TABLE 12.14: Features of Different Bioprinting Techniques
  • TABLE 12.15: Bioprinting of iPSC-derived Tissues
  • TABLE 12.16: Achievements made using iPSCs for the Conservation of Animals
  • TABLE 12.17: Two Companies using iPSCs for Cultured Meat Production
  • TABLE 13.1: Estimated Global Market for iPSCs by Geography, 2021-2029
  • TABLE 13.2: Estimated Global Market for iPSCs by Technology, 2021-2029
  • TABLE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2021-2029
  • TABLE 13.4: Global Market for iPSCs by Derived Cell Type, 2021-2029
  • TABLE 14.1: Aspen's Clinical Pipeline
  • TABLE 14.2: iPS Cell Lines from CET
  • TABLE 14.3: Century Therapeutics' Pipeline Products
  • TABLE 14.4: Cytovia's Product Pipeline
  • TABLE 14.5: Fate Therapeutic's Product Pipeline
  • TABLE 14.6: HebeCell's Product Pipeline
  • TABLE 14.7: Healios' Research and Development Status
  • TABLE 14.8: Hopstem's Product Pipeline
  • TABLE 14.9: LizarBio's Pipeline Products
  • TABLE 14.10: Megakaryon's Multiple Pipelines for iPS Platelet Products
  • TABLE 14.11: StemRNA Human iPSCs from ReproCELL
  • TABLE 14.12: Thya's Product Pipeline

INDEX OF FIGURES

  • FIGURE 3.1: Manufacturing Timeline for Autologous iPSC-derived Cell Products
  • FIGURE 3.2: Manufacturing Cost for Manual and Automated Processes
  • FIGURE 3.3: Technical Set-up of the StemCellFactory (SCF)
  • FIGURE 3.4: Share of iPSC-based Research within the Overall Stem Cell Industry
  • FIGURE 3.5: Major Focuses of iPSC Companies
  • FIGURE 3.6: Commercially Available iPSC-derived Cell Types
  • FIGURE 3.7: Relative use of iPSC-derived Cell Types in Toxicology Testing Assays
  • FIGURE 3.8: Schematic Comparing Nucleofection and Lipofection
  • FIGURE 3.9: Schematic of Steps involved in Platelet Production
  • FIGURE 5.1: Number of Research Publications on iPSCs in PubMed.gov, 2006 - 2022
  • FIGURE 5.2: Number of Published Papers in Pathophysiological Research, 2006 - 2022
  • FIGURE 5.3: Number of PubMed Papers in Reprogramming, 2008 - 2022
  • FIGURE 5.4: Number of PubMed papers on iPSC Differentiation, 2006 - 2022
  • FIGURE 5.5: PubMed Papers on the use of iPSCs in Drug Discovery
  • FIGURE 5.6: PubMed Papers on the use of iPSCs in Cell Therapy
  • FIGURE 5.7: Percent Share of Published Articles by Disease Type
  • FIGURE 5.8: Percent Share of Articles by Country
  • FIGURE 6.1: Legal Status of iPSC Patents
  • FIGURE 6.2: Patents by Assignee Organization Type
  • FIGURE 6.3: Ownership of Patent Families by Assignee Type
  • FIGURE 6.4: Number of Patent Families by Top Ten Countries
  • FIGURE 6.5: Number of Patent Families Filed by Year. 2006-2020
  • FIGURE 6.6: Percent Share of Patents Representing Different Disorders
  • FIGURE 6.7: Percent Share of Patents on iPSC Preparation Methods
  • FIGURE 6.8: Percent Share of Patents Related to Cell Types Differentiated from iPSCs
  • FIGURE 6.9: Percent Share of Patent Applications for Disease-Specific Technologies
  • FIGURE 7.1: Number of iPSC Clinical Trials by Year, 2006-2022
  • FIGURE 7.2: Study Designs in iPSC Clinical Trials
  • FIGURE 7.3: Therapeutic and Non-Therapeutic Studies
  • FIGURE 7.4: Non-Therapeutic Clinical Trials by Use
  • FIGURE 7.5: Top Ten Countries with the Ongoing Non-Therapeutic Studies
  • FIGURE 7.6: Diseases Targeted by Non-Therapeutic Studies
  • FIGURE 7.7: Therapeutic Studies by Type of iPSCs Used
  • FIGURE 7.8: Therapeutic Studies by Phase of Study
  • FIGURE 7.9: Therapeutic Studies by Disease Type
  • FIGURE 8.1: Number of NIH Funding for iPSC Projects, 2010 - 2022
  • FIGURE 8.2: Value of NIH Funding for iPSC Research, 2010 - 2022
  • FIGURE 10.1: Overview of iPSC Technology
  • FIGURE 10.2: Generation of iPSCs from MEF Cultures using 24 Factors by Yamanaka
  • FIGURE 10.3: The Roles of OSKM Factors in the Induction of iPSCs
  • FIGURE 10.4: Schematic of Delivery Methods for iPSC Induction
  • FIGURE 10.5: Schematic of Retroviral Delivery Method
  • FIGURE 10.6: Schematic of Lentiviral Delivery
  • FIGURE 10.7: piggyBac (PB) Transposon Delivery
  • FIGURE 10.8: Adenoviral Vector Delivery
  • FIGURE 10.9: oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1) based Episomes
  • FIGURE 10.10: RNA Delivery
  • FIGURE 10.11: Protein Delivery
  • FIGURE 11.1: Workflow in iPSC Banks
  • FIGURE 12.1: Biomedical Applications of iPSCs: An Overview
  • FIGURE 12.2: Basic Cell Types Differentiated from iPSCs
  • FIGURE 12.3: Advantages of iPSCs in Drug Discovery
  • FIGURE 12.4: iPSCs and their Potential for Toxicity Testing and Drug Screening
  • FIGURE 12.5: Testing Drugs for Drug Induced Liver Injury using iPSCs
  • FIGURE 12.6: Relative use of IPSC-derived Cell Types in Toxicity Testing Studies
  • FIGURE 12.7: Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
  • FIGURE 12.8: Schematic of Techniques used for iPSC Bioprinting
  • FIGURE 12.9: Schematic Showing the use of iPSCs in Protecting Endangered Species
  • FIGURE 12.10: General Workflow for Cultured Meat Production
  • FIGURE 13.1: Estimated Global Market for iPSCs by Geography through 2029
  • FIGURE 13.2: Estimated Global Market for iPSCs by Technology through 2029
  • FIGURE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2021-2029
  • FIGURE 13.4: Estimated Global Market for iPSCs by Derived Cell Type, 2022
  • FIGURE 14.1: Century's Approach in iPSC Therapy
  • FIGURE 14.2: Elixirgen's iPSCs Differentiation
  • FIGURE 14.3: MyCell Custom Services
  • FIGURE 14.4: Hopstem's Research & Development
  • FIGURE 14.5: Kytopen's Push Button System
  • FIGURE 14.6: Manufacturing Flow of Products from Magakaryon
  • FIGURE 14.7: Treatable Diseases by Products from Megakaryon
  • FIGURE 14.8: Schematic of developing iPSC Neurons by SynFire Technology
  • FIGURE 14.9: Cardio quickPredict Process
  • FIGURE 14.10: Scematic of Thya's iTCR-T (iPSC-derived TCR-T)
  • FIGURE 14.11: Thya's iCAR-NK/ILC (iPSC-derived CAR-NK/ILC)
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제